Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Radiotherapy plus adjuvant temozolomide for the treatment of glioblastoma—a paradigm shift

Nature Clinical Practice Oncology volume 2, pages 334–335 (2005)Cite this article

boxed-textStupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Laperriere N et al.; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64: 259–273

  2. Fine HA et al. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597

    Article  CAS  Google Scholar 

  3. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011–1018

    Article  CAS  Google Scholar 

  4. Hegi ME et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Chief of the Neuro-Oncology Branch at the National Cancer Institute, Bethesda, MD, USA

    Howard A Fine

Authors
  1. Howard A Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard A Fine.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

WHO GRADE IV ASTROCYTOMA

A high-grade brain tumor that forms from glial (supportive) tissue of the brain; also called glioblastoma multiforme

HAZARD RATIO (HR)

The relative likelihood of experiencing a particular event; an HR of 0.5 indicates that one group has half the risk of the other group

COX MULTIVARIATE MODEL

Statistical regression technique which takes into account the time interval to an outcome in relation to baseline characteristics (of a patient)

NITROSOUREAS

Any of several chemically related antineoplastic agents including carmustine, lomustine, semustine, and the antibiotic streptozocin

EPIGENETIC SILENCING

Inappropriate repression of gene expression caused by increased genomic heterochromatinization; epigenetic silencing of gene promoter regions can be caused by DNA methylation and histone deacetylation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fine, H. Radiotherapy plus adjuvant temozolomide for the treatment of glioblastoma—a paradigm shift. Nat Rev Clin Oncol 2, 334–335 (2005). https://doi.org/10.1038/ncponc0204

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0204

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing